ClinicalTrials.gg
Active, not recruitingNCT06689215Updated Feb 13, 2026

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

An observational study in Heart Failure, Congestive, sponsored by Nihon Kohden. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Nihon Kohden · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
433rd of 552
30 · median 150
Started
2024
with 108 others
Observational
553 of 2,159
102 open now
Primary completion
2026-03
later than 72 of 438 live
Registered
1,963rd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 433rd largest by planned enrollment of the 552 observational ones that give a count, is one of 109 that started in 2024, is one of 553 observational ones, reaches primary completion later than 72 of the 438 other live ones, and was the 1,963rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

Comparison of a non-invasive method of measuring central venous pressure to the conventional modality of invasive central venous pressure.

Read the detailed description

The conventional method used to measure central venous pressure has limitations since it is an invasive procedure that requires a central venous catheter. To overcome this challenge, a new technology to assess CVP non-invasively using an oscillometric method is being developed. It is called enclosed zone central venous pressure (ezCVP). A comparison study of ezCVP and CVP is needed to determine accuracy and reproducibility.

03

Conditions studied

  • Heart Failure, Congestive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the Stanford University Hospital ICU with central venous catheter.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult age over 18 years.
  2. Arm circumference is 18 cm to 55 cm
  3. Subject will have an existing indwelling central venous catheter during their ICU stay
  4. Subject or legally authorized representative (LAR) is able to understand the risks and potential benefits of participating in the study and is willing to provide written
  5. Subject or LAR is willing and able to comply with protocol procedures

Exclusion criteria

Exclusion Criteria:

  1. Finger and/or upper arm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor and/or blood pressure cuff.
  2. Pregnant (self-reported)
  3. Upper extremity deep venous thrombosis currently being treated
  4. Severe skin disease involving the upper arm(s)
  5. Study investigator may exclude patients based on clinical judgement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • DeviceNon-invasive central venous pressure

    Non-invasive method to measure central venous pressure indicator

    Also known as: ezCVP, CVPni

06

What researchers measure

Primary outcomes

  1. Non-invasive pressure indicator

    Evaluate sensitivity and specificity of ezCVP indication based on the case where CVP is in a 'low range' (0 \< CVP \< 10 mmHg) or 'high range' (\>= 10 mmHg)

    Time frame: 1-7 days

Secondary outcomes

  1. Direction of change

    Correlate the directionality of ezCVP change to invasive CVP change over time (i.e., increasing, decreasing or remaining stable).

    Time frame: 1-7 days

  2. Correlation with invasive CVP

    Quantify the agreement between ezCVP (non-invasive) and CVP (invasive)

    Time frame: 1-7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared. Aggregate results will be published by the investigators in academic journals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Mar 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 30, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06689215
Lead sponsor
Nihon Kohden
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Oct 21, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Masataka Kawana, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion